ヒトのk-オピオイド受容体の構造は,JDTicとの複合体である
Huixian Wu1, Daniel Wacker, Mauro Mileni
1Department of Molecular Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, USA.
Nature
|March 23, 2012
まとめ
研究者らは,ヒトのカッパ・オピオイド受容体 (κ-OR) の結晶構造を決定し,その受容体は抗体と結合している. これは κ-ORの選択性と,痛みと気分調節のための薬物設計に関する重要な洞察を提供します.
科学分野:
- 構造生物学 構造生物学とは
- 神経科学は神経科学である.
- 薬理学 薬理学とは
背景:
- カッパ-オピオイド受容体 (κ-OR) を含むオピオイド受容体は,痛み,気分,呼吸などの重要な生理学的プロセスを調節します.
- κ-ORは,特にディスフォリアと精神相似効果と関連しており,治療介入のターゲットとなっています.
研究 の 目的:
- 人間の κ-OR のリガンド結合と亜型選択性の構造的基礎を解明する.
- 新型 κ-OR ターゲティング化合物の合理的な設計のための分子洞察を提供する.
主な方法:
- 2.9 Åの解像度で選択的敵対体JDTicとの複合体におけるヒト κ-OR の結晶構造を決定した.
- アンタゴニストとアゴニストを含む様々な κ-OR リガンドの結合を分析するために分子モデリングを使用しました.
- サイト・ディレクテッド・ミュータゲネシスを実行し,構造的発見を検証するために,リガンドの構造-活性関係を分析した.
主要な成果:
- JDTic-bound κ-ORの詳細なアーキテクチャを明らかにし,高い親和性と選択性を有するリガンド結合ポケットの特徴を強調しました.
- モルフィナンの派生物やディターペンの類型を含む様々な化学型に対する共通で独特の結合相互作用を特定した.
- ミュタゲネシスと構造-活性関係分析を通じて,鍵となるアミノ酸の相互作用が確認されました.
結論:
- 結晶構造は,ヒトの κ-OR.の亜型選択性の高い分子説明を提供する.
- これらの発見は,治療目的で κ-OR を標的とする新しい薬理学的剤の設計に不可欠な洞察を提供します.
さらに関連する動画
07:48Tracking Drug-induced Changes in Receptor Post-internalization Trafficking by Colocalizational Analysis
Published on: July 3, 2015
18:45Harvesting and Cryo-cooling Crystals of Membrane Proteins Grown in Lipidic Mesophases for Structure Determination by Macromolecular Crystallography
Published on: September 2, 2012
関連する概念動画
01:22Opioid Receptors: Overview
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2, D-Pen5]-enkephalin or DPDPE for...
01:30Ligand-Gated Ion Channel Receptor: Gating Mechanism
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
01:25Drug-Receptor Interaction: Agonist
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
01:30Transducer Mechanism: G Protein–Coupled Receptors
G Protein–Coupled Receptors (GPCRs) are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to various stimuli. GPCRs regulate critical physiological pathways and are excellent drug targets for treating diseases such as diabetes, cancer, obesity, depression, or Alzheimer's. Nearly 35% of approved drugs implement their therapeutic effects by selectively interacting with specific GPCRs.
GPCRs are also called heptahelical, 7TM, or...
GPCRs are also called heptahelical, 7TM, or...
01:29The Two-State Receptor Model
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with one...
The binding affinity of a drug determines its interaction with one...
01:30Assembly of Signaling Complexes
Multiprotein signaling complexes are formed in a dynamic process involving protein-protein interactions at the cytoplasmic domain of transmembrane receptors or enzymatic and non-enzymatic proteins associated with the receptor. These complexes ensure the activation and propagation of intracellular signals that regulate cell functions.
Interaction domains in cell signaling
Interaction domains recognize exposed features of their binding partners containing post-translationally modified sequences,...
Interaction domains in cell signaling
Interaction domains recognize exposed features of their binding partners containing post-translationally modified sequences,...